Isomorphic Labs has a Nobel Prize-winning platform, $600 million in fresh capital, and partnerships worth up to $3 billion with Eli Lilly and Novartis. Its first AI-designed drug was supposed to enter human clinical trials by end of 2025. It didn't. What the delay reveals about the gap between computational elegance and biological proof.

Claude Mythos Preview can autonomously find and exploit zero-day vulnerabilities in every major operating system and browser. Rather than shelve it, Anthropic has handed it to a coalition of 50-plus firms under Project Glasswing. The strategy is defensible. Whether it holds depends on who else is building the same thing - and Washington's posture toward the company that built it.

Google DeepMind's Gemini 3.1 Pro arrived with the strongest independently verified reasoning scores of any frontier model. Three weeks later, GPT-5.4 changed the picture. A benchmark-by-benchmark assessment of where Gemini still leads, where it has fallen behind, and what the competitive gap actually looks like on verified data.

SoftBank wired its first $10 billion OpenAI tranche today - borrowed in full from JPMorgan, Goldman Sachs, and three Japanese banks on a 12-month unsecured loan. The deal's architecture reveals more about its risks than its headline number does.